Gossamer Bio, Inc. (GOSS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$9.42-5.33%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · GOSS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 364.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -63.4% |
Growth built into the price is above our model estimate.
The price assumes 428.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
GOSS — litigation filed
Dated 2026-09-23
Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“PAH”). This is the Company’s first NDA submission. The NDA is supported by the Company’s Phase 3 PROSERA Study as one adequate and well-controlled clinical investigation, together with confirmatory evidence from the Company’s Ph…
Why it matters: The FDA called the study’s result size and statistical strength review issues. Its review will test whether the evidence can support approval.
Watch forFDA finds PROSERA and TORREY evidence adequate. No new trial is needed to assess benefit and risk.
Also watch forFDA says the evidence is not enough. The benefits and risks do not support approval, or another trial is needed.
Why it matters: FDA acceptance would let the review move forward. A refusal would raise a key risk for Gossamer’s only program.
Watch forFDA accepts the NDA for review and sets a decision date, with no request for a new study before review.
Also watch forFDA refuses to file the NDA or asks for new clinical evidence before filing.
Why it matters: Gossamer completed a reverse split in September. A lasting rise above Nasdaq’s minimum bid price would reduce listing risk.
Watch forNasdaq confirms GOSS meets the minimum bid-price rule after the split and keeps its listing in good standing.
Also watch forNasdaq says GOSS remains below the minimum bid price or issues a new compliance notice.
Why it matters: Gossamer reported $57 million in cash and said it could fund costs into Q1 2027. A longer runway would ease near-term funding pressure.
Watch forAt the November 4 earnings update, cash guidance extends beyond Q1 2027 without a new share or debt raise.
Also watch forThe company reports its cash runway ends before Q1 2027 or announces a new share or debt raise to fund operations.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$349 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $1,064 loss on $10,000 · 10.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,722 loss on $10,000 · 97.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.